These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 21972433)

  • 1. When to start treatment? A systematic approach to the comparison of dynamic regimes using observational data.
    Cain LE; Robins JM; Lanoy E; Logan R; Costagliola D; Hernán MA
    Int J Biostat; 2010; 6(2):Article 18. PubMed ID: 21972433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emulating a trial of joint dynamic strategies: An application to monitoring and treatment of HIV-positive individuals.
    Caniglia EC; Robins JM; Cain LE; Sabin C; Logan R; Abgrall S; Mugavero MJ; Hernández-Díaz S; Meyer L; Seng R; Drozd DR; Seage Iii GR; Bonnet F; Le Marec F; Moore RD; Reiss P; van Sighem A; Mathews WC; Jarrín I; Alejos B; Deeks SG; Muga R; Boswell SL; Ferrer E; Eron JJ; Gill J; Pacheco A; Grinsztejn B; Napravnik S; Jose S; Phillips A; Justice A; Tate J; Bucher HC; Egger M; Furrer H; Miro JM; Casabona J; Porter K; Touloumi G; Crane H; Costagliola D; Saag M; Hernán MA
    Stat Med; 2019 Jun; 38(13):2428-2446. PubMed ID: 30883859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal frequency of CD4 cell count and HIV RNA monitoring prior to initiation of antiretroviral therapy in HIV-infected patients.
    Kimmel AD; Goldie SJ; Walensky RP; Losina E; Weinstein MC; Paltiel AD; Zhang H; Freedberg KA;
    Antivir Ther; 2005; 10(1):41-52. PubMed ID: 15751762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. When to start antiretroviral therapy in resource-limited settings.
    Walensky RP; Wolf LL; Wood R; Fofana MO; Freedberg KA; Martinson NA; Paltiel AD; Anglaret X; Weinstein MC; Losina E;
    Ann Intern Med; 2009 Aug; 151(3):157-66. PubMed ID: 19620143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy.
    Cain LE; Saag MS; Petersen M; May MT; Ingle SM; Logan R; Robins JM; Abgrall S; Shepherd BE; Deeks SG; John Gill M; Touloumi G; Vourli G; Dabis F; Vandenhende MA; Reiss P; van Sighem A; Samji H; Hogg RS; Rybniker J; Sabin CA; Jose S; Del Amo J; Moreno S; Rodríguez B; Cozzi-Lepri A; Boswell SL; Stephan C; Pérez-Hoyos S; Jarrin I; Guest JL; D'Arminio Monforte A; Antinori A; Moore R; Campbell CN; Casabona J; Meyer L; Seng R; Phillips AN; Bucher HC; Egger M; Mugavero MJ; Haubrich R; Geng EH; Olson A; Eron JJ; Napravnik S; Kitahata MM; Van Rompaey SE; Teira R; Justice AC; Tate JP; Costagliola D; Sterne JA; Hernán MA;
    Int J Epidemiol; 2016 Dec; 45(6):2038-2049. PubMed ID: 26721599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study.
    Guiguet M; Boué F; Cadranel J; Lang JM; Rosenthal E; Costagliola D;
    Lancet Oncol; 2009 Dec; 10(12):1152-9. PubMed ID: 19818686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV diagnosis at CD4 count above 500 cells/mm3 and progression to below 350 cells/mm3 without antiretroviral therapy.
    UK Collaborative HIV Cohort (CHIC) Study Steering Committee
    J Acquir Immune Defic Syndr; 2007 Nov; 46(3):275-8. PubMed ID: 18172938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study.
    ; Cain LE; Logan R; Robins JM; Sterne JA; Sabin C; Bansi L; Justice A; Goulet J; van Sighem A; de Wolf F; Bucher HC; von Wyl V; Esteve A; Casabona J; del Amo J; Moreno S; Seng R; Meyer L; Perez-Hoyos S; Muga R; Lodi S; Lanoy E; Costagliola D; Hernan MA
    Ann Intern Med; 2011 Apr; 154(8):509-15. PubMed ID: 21502648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal CD4 count for initiating HIV treatment: impact of CD4 observation frequency and grace periods, and performance of dynamic marginal structural models.
    Ewings FM; Ford D; Walker AS; Carpenter J; Copas A
    Epidemiology; 2014 Mar; 25(2):194-202. PubMed ID: 24487204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term follow-up of asymptomatic HIV-infected patients who discontinued antiretroviral therapy.
    Fernández Guerrero ML; Rivas P; Molina M; Garcia R; De Górgolas M
    Clin Infect Dis; 2005 Aug; 41(3):390-4. PubMed ID: 16007538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count.
    García F; de Lazzari E; Plana M; Castro P; Mestre G; Nomdedeu M; Fumero E; Martínez E; Mallolas J; Blanco JL; Miró JM; Pumarola T; Gallart T; Gatell JM
    J Acquir Immune Defic Syndr; 2004 Jun; 36(2):702-13. PubMed ID: 15167289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Total lymphocyte count as a surrogate marker for CD4+ t cell count in initiating antiretroviral therapy at Kenyatta National Hospital, Nairobi.
    Gitura B; Joshi MD; Lule GN; Anzala O
    East Afr Med J; 2007 Oct; 84(10):466-72. PubMed ID: 18232267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimating the optimal CD4 count for HIV-infected persons to start antiretroviral therapy.
    Shepherd BE; Jenkins CA; Rebeiro PF; Stinnette SE; Bebawy SS; McGowan CC; Hulgan T; Sterling TR
    Epidemiology; 2010 Sep; 21(5):698-705. PubMed ID: 20585252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naive adults.
    Siegfried N; Uthman OA; Rutherford GW
    Cochrane Database Syst Rev; 2010 Mar; 2010(3):CD008272. PubMed ID: 20238364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater.
    Gras L; Kesselring AM; Griffin JT; van Sighem AI; Fraser C; Ghani AC; Miedema F; Reiss P; Lange JM; de Wolf F;
    J Acquir Immune Defic Syndr; 2007 Jun; 45(2):183-92. PubMed ID: 17414934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of long-term non-progressor and HIV controller status over time in the French Hospital Database on HIV - ANRS CO4.
    Grabar S; Selinger-Leneman H; Abgrall S; Pialoux G; Weiss L; Costagliola D
    PLoS One; 2017; 12(10):e0184441. PubMed ID: 28968404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: results from the EuroSIDA study.
    Miller V; Mocroft A; Reiss P; Katlama C; Papadopoulos AI; Katzenstein T; van Lunzen J; Antunes F; Phillips AN; Lundgren JD
    Ann Intern Med; 1999 Apr; 130(7):570-7. PubMed ID: 10189326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A decision tree to help determine the best timing and antiretroviral strategy in HIV-infected patients.
    Piroth L; Fournel I; Mahy S; Yazdanpanah Y; Rey D; Rabaud C; Faller JP; Hoen B; Fardeheb M; Quantin C; Chavanet P; Binquet C;
    Epidemiol Infect; 2011 Dec; 139(12):1835-44. PubMed ID: 21232172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and factors predicting the duration of first and second treatment interruptions guided by CD4+ cell counts in patients with chronic HIV infection.
    Boschi A; Tinelli C; Ortolani P; Arlotti M
    J Antimicrob Chemother; 2006 Mar; 57(3):520-6. PubMed ID: 16387747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiretroviral therapy in 1999 for antiretroviral-naive individuals with HIV infection.
    Fischl MA
    AIDS; 1999 Sep; 13 Suppl 1():S49-59. PubMed ID: 10546785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.